Digestive Enzymes After Gastrectomy

This single-study briefing covers the PANEM trial protocol, which evaluates oral pancreatic digestive enzyme supplementation after partial or total gastrectomy. The protocol frames altered coordination between chyme and pancreatic enzymes after gastric surgery as a potential contributor to maldigestion, malabsorption, discomfort, steatorrhea, malnourishment, and diminished quality of life. It does not report comparative treatment outcomes. pmid:42771661

Evidence

PANEM is reported as an investigator-initiated, randomized, phase III, parallel-arm, placebo-controlled, double-blind, multi-center superiority trial. Its population is adults after partial or total gastrectomy. Participants are randomized in a 1:1 ratio to digestive enzyme therapy or placebo, with the assigned treatment taken for 6 months after surgery. The protocol identifies the trial medication as NORTASE and states that both digestive enzymes and placebo are taken orally with meals. pmid:42771661

The planned sample is 188 randomized patients. The primary outcome is cancer-specific quality of life, defined as the physical sub-score of the EORTC-QLQ-C30 at six months. Secondary outcomes include other quality-of-life measures, weight loss, use of supplemental nutrition, and laboratory measurements related to malnutrition and metabolism. These endpoints make the study relevant to digestion and nutrition, while retaining quality of life as its principal efficacy focus. pmid:42771661

The protocol says that the trial was designed because evidence on digestive enzyme therapy after gastrectomy is limited and methodologically constrained. It also describes prior trials in this setting as lacking and notes that reviews characterized the apparent effects of pancreatic enzymes in gastrectomized patients as small while judging the evidence insufficient. These statements provide the rationale for a blinded placebo comparison, rather than evidence that the intervention is effective. pmid:42771661

No treatment-effect estimate, confidence interval, or outcome p-value is reported in the described material. The available source is a clinical trial protocol, so the comparison of digestive enzymes with placebo remains a planned evaluation rather than a reported result. Accordingly, the source supports describing the study question, design, population, intervention, comparator, and outcomes, but not a conclusion about whether supplementation improves quality of life, weight loss, nutritional support use, or laboratory measures. pmid:42771661

Analysis — Protocol Interpretation

The protocol is well aligned with the clinical uncertainty it seeks to address. A randomized, double-blind, placebo-controlled design can reduce biases that would otherwise complicate interpretation of symptom, quality-of-life, and nutrition-related outcomes after major gastric surgery. Including both partial and total gastrectomy broadens the enrolled postoperative population, although the supplied material does not provide outcome data by surgical subgroup. The use of a physical EORTC-QLQ-C30 sub-score as the primary endpoint gives the trial a patient-centered main outcome, while the secondary measures recognize that postoperative nutrition may be reflected across body weight, nutritional supplementation, and laboratory measures rather than by a single indicator. pmid:42771661

The central interpretive boundary is that this is a protocol, not a completed efficacy report. The planned placebo comparator and six-month assessment can establish a framework for estimating benefit and uncertainty once results are available, but they do not themselves demonstrate benefit. The protocol’s discussion of maldigestion and malabsorption explains a biological and clinical rationale for enzyme supplementation, yet rationale is not a treatment effect. Likewise, a future statistically significant comparison would require separate assessment of its magnitude and clinical significance; statistical significance alone would not establish a clinically important improvement. pmid:42771661

For readers tracking digestion and nutrition research, PANEM is best treated as a study to watch for reported comparative results. Its secondary outcomes could help clarify whether any quality-of-life pattern is accompanied by changes in weight loss, supplemental nutrition, or laboratory measures related to malnutrition and metabolism. Until those results are reported, it would be premature to characterize pancreatic digestive enzymes as improving any of those outcomes after gastrectomy. pmid:42771661

Limitations

The evidence in this briefing is limited to a single protocol. It reports a planned trial rather than observed treatment outcomes, so there is no reported effect size, confidence interval, or outcome p-value to assess. The supplied material also describes earlier evidence as limited, with small sample sizes and low-quality trials noted in reviews. These limitations mean that the protocol’s rationale and design should not be conflated with evidence of benefit, lack of benefit, or clinical significance. pmid:42771661